Home » Treatment and Research » Medication Overview

Medication Overview

Need new introductory text here…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla vitae laoreet est. Duis interdum laoreet massa, at blandit libero cursus at. In est magna, porta quis massa vitae, tincidunt venenatis ligula.

Action items for Medication Overview

Visit these 3 links for in-depth information and articles

Action item one

Action item two

Action item three

For a deeper dive into this topic you’ll find additional information here.

FEATURE

TBD - will add after article migration

ADDITIONAL READING

September 22, 2022

ASH 2021: Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of “Positive” Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 – 2015

Dr. David Cucchi and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021).

September 22, 2022

ASH 2021: Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Dr. Javier Pinilla Ibarz and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021).

July 13, 2022

ASH 2021: Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL)

Dr. Matthew Davids and colleagues presented this research at the American Society for Hematology annual meeting held in December 2021 (ASH 2021).

June 2, 2022

ASH 2021: Dr. Jennifer Woyach on a Clinical Trial in Progress with Combination Ibrutinib, Venetoclax, and Obinutuzumab

Discussion of a phase 3 clinical trial in progress, investigating the efficacy of the triple combination of ibrutinib plus venetoclax and obinutuzumab with response-dependent discontinuation.

April 8, 2022

ASH 2021: Dr. Constantine Tam on Zanubrutinib in Combination with Venetoclax for Patients with Deletion 17p

CLL and SLL patients with deletion 17p do not respond well to chemoimmunotherapy. But new targeted therapies may help. Zanubrutinib is a next-generation BTK inhibitor being tested in combination with venetoclax for treating patients with deletion 17p. Results from a Phase III trial of this combination were presented at

March 30, 2022

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a

Treatment and Research

Relapsed/Refractory or Later Therapies

MRD and Disease Monitoring

RECENT NEWS

When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.

Update to the FDA Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld

Nurses Note: Special Considerations for Those with CLL/SLL When Preparing for Floods and Other Natural Disasters

ASH 2021: Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

ASH 2021: Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of “Positive” Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 – 2015

ASH 2021: Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Medication Overview

Action items for Medication Overview

Action item one

Action item two

Action item three

FEATURE

TBD - will add after article migration

ADDITIONAL READING

ASH 2021: Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of “Positive” Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 – 2015

ASH 2021: Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

ASH 2021: Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL)

ASH 2021: Dr. Jennifer Woyach on a Clinical Trial in Progress with Combination Ibrutinib, Venetoclax, and Obinutuzumab

ASH 2021: Dr. Constantine Tam on Zanubrutinib in Combination with Venetoclax for Patients with Deletion 17p

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

RECENT NEWS

Update to the FDA Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld

Nurses Note: Special Considerations for Those with CLL/SLL When Preparing for Floods and Other Natural Disasters

ASH 2021: Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

ASH 2021: Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of “Positive” Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 – 2015

ASH 2021: Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Dr. Shmuel Shoham on Convalescent Plasma for COVID-19 in Immunocompromised Patients

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT